BAX
insider transactionsBAXTER INTERNATIONAL INC — buys & sells by directors, officers and 10% owners A shareholder owning more than 10% of the company. Must report trades, but usually a weaker signal than an officer or director. (SEC Form 4).
No open-market buys or sells this period. The trades below are grants, option exercises and gifts, which carry no market price.
Net buy / sell volume
Not enough data to chart yet.
Tap or hover the chart for daily net volume. Green = net buying, red = net selling.
All transactions
-
Other·F
President, Adv. Surgery
$2.9K
153 sh · $18.68
Own -0%
-
Other·F
James Teaff KEY
President, CCS
$6.0K
321 sh · $18.68
Own -1%
-
Grant·A
SVP, Interim CFO, CAO & Cntrlr
$0
13.4K sh
Own +29%
-
Grant·A
Director
$0
12.8K sh
Own +53%
-
Grant·A
Director
$0
12.8K sh
Own +41%
-
Grant·A
Director
$0
12.8K sh
Own +58%
-
Grant·A
Director
$0
12.8K sh
Own +43%
-
Grant·A
Director
$0
12.8K sh
Own +21%
-
Grant·A
Director
$0
12.8K sh
Own +709%
-
Grant·A
Director
$0
12.8K sh
Own +119%
-
Grant·A
Director
$0
12.8K sh
Own +73%
-
Other·F
SVP, CAO and Controller
$34.2K
1.9K sh · $17.69
Own -4%
-
Other·F
Group Pres., ITT & Pharma.
$50.4K
2.8K sh · $17.69
Own -4%
-
Other·F
EVP and General Counsel
$117.1K
6.6K sh · $17.69
Own -5%
-
Other·F
EVP,Group Pres,Healthcare
$224.2K
12.7K sh · $17.69
Own -9%
-
Other·F
Joel T. Grade KEY
EVP and CFO
$144.2K
8.2K sh · $17.69
Own -3%
-
Other·F
EVP,Group Pres,Healthcare
$31.8K
1.6K sh · $19.69
Own -1%
-
Other·F
Group Pres., ITT & Pharma.
$36.5K
1.9K sh · $19.69
Own -2%
-
Other·F
EVP and General Counsel
$26.3K
1.3K sh · $19.69
Own -1%
-
Grant·A
Andrew P. Hider KEY
President and CEO
$0
488.5K sh
Own New
-
Grant·A
Andrew P. Hider KEY
President and CEO
$0
201.8K sh
Own +54%
-
Grant·A
Cynthia Carlisle KEY
Executive Vice President, CHRO
$0
43.1K sh
Own New
-
Grant·A
Cynthia Carlisle KEY
Executive Vice President, CHRO
$0
11.9K sh
Own +67%
-
Grant·A
Cynthia Carlisle KEY
Executive Vice President, CHRO
$0
17.8K sh
Own New
-
Grant·A
Group Pres., ITT & Pharma.
$0
57.5K sh
Own New
-
Grant·A
Group Pres., ITT & Pharma.
$0
23.7K sh
Own +42%
-
Grant·A
EVP and General Counsel
$0
64.7K sh
Own New
-
Grant·A
EVP and General Counsel
$0
26.7K sh
Own +22%
-
Grant·A
Joel T. Grade KEY
EVP and CFO
$0
103.4K sh
Own New
-
Grant·A
Joel T. Grade KEY
EVP and CFO
$0
42.7K sh
Own +18%
-
Grant·A
SVP, CAO and Controller
$0
30.9K sh
Own +178%
-
Grant·A
Director
$0
1.8K sh
Own New
-
Other·F
Group Pres., ITT & Pharma.
$19.9K
918 sh · $21.73
Own -2%
-
Grant·A
Group Pres., ITT & Pharma.
$0
2.3K sh
Own +4%
-
Other·F
EVP and General Counsel
$113.5K
5.2K sh · $21.73
Own -4%
-
Grant·A
EVP and General Counsel
$0
17.1K sh
Own +16%
-
Other·F
EVP,Group Pres,Healthcare
$125.4K
5.8K sh · $21.73
Own -4%
-
Grant·A
EVP,Group Pres,Healthcare
$0
19.0K sh
Own +15%
-
Other·F
Joel T. Grade KEY
EVP and CFO
$198.7K
9.1K sh · $21.73
Own -4%
-
Grant·A
Joel T. Grade KEY
EVP and CFO
$0
30.5K sh
Own +14%
| Date▾ | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Jun 2, 2026 | Steven P. Wallace KEY | Other F | 153 | $2.9K |
| Jun 2, 2026 | James Teaff KEY | Other F | 321 | $6.0K |
| Jun 1, 2026 | Anita A Zielinski KEY | Grant A | 13.4K | $0 |
| May 5, 2026 | David S. Wilkes | Grant A | 12.8K | $0 |
| May 5, 2026 | Amy Mcbride Wendell | Grant A | 12.8K | $0 |
| May 5, 2026 | Nancy M Schlichting | Grant A | 12.8K | $0 |
| May 5, 2026 | Patricia Morrison | Grant A | 12.8K | $0 |
| May 5, 2026 | David Brent Shafer | Grant A | 12.8K | $0 |
| May 5, 2026 | Michael R. Mcdonnell | Grant A | 12.8K | $0 |
| May 5, 2026 | Jeffrey A Craig | Grant A | 12.8K | $0 |
| May 5, 2026 | William A. Ampofo II | Grant A | 12.8K | $0 |
| Mar 6, 2026 | Anita A Zielinski | Other F | 1.9K | $34.2K |
| Mar 6, 2026 | Maria Cecilia Soriano | Other F | 2.8K | $50.4K |
| Mar 6, 2026 | David S. Rosenbloom | Other F | 6.6K | $117.1K |
| Mar 6, 2026 | Reazur Rasul | Other F | 12.7K | $224.2K |
| Mar 6, 2026 | Joel T. Grade KEY | Other F | 8.2K | $144.2K |
| Mar 2, 2026 | Reazur Rasul | Other F | 1.6K | $31.8K |
| Mar 2, 2026 | Maria Cecilia Soriano | Other F | 1.9K | $36.5K |
| Mar 2, 2026 | David S. Rosenbloom | Other F | 1.3K | $26.3K |
| Feb 27, 2026 | Andrew P. Hider KEY | Grant A | 488.5K | $0 |
| Feb 27, 2026 | Andrew P. Hider KEY | Grant A | 201.8K | $0 |
| Feb 27, 2026 | Cynthia Carlisle KEY | Grant A | 43.1K | $0 |
| Feb 27, 2026 | Cynthia Carlisle KEY | Grant A | 11.9K | $0 |
| Feb 27, 2026 | Cynthia Carlisle KEY | Grant A | 17.8K | $0 |
| Feb 27, 2026 | Maria Cecilia Soriano | Grant A | 57.5K | $0 |
| Feb 27, 2026 | Maria Cecilia Soriano | Grant A | 23.7K | $0 |
| Feb 27, 2026 | David S. Rosenbloom | Grant A | 64.7K | $0 |
| Feb 27, 2026 | David S. Rosenbloom | Grant A | 26.7K | $0 |
| Feb 27, 2026 | Joel T. Grade KEY | Grant A | 103.4K | $0 |
| Feb 27, 2026 | Joel T. Grade KEY | Grant A | 42.7K | $0 |
| Feb 27, 2026 | Anita A Zielinski | Grant A | 30.9K | $0 |
| Feb 13, 2026 | Michael R. Mcdonnell | Grant A | 1.8K | $0 |
| Feb 9, 2026 | Maria Cecilia Soriano | Other F | 918 | $19.9K |
| Feb 9, 2026 | Maria Cecilia Soriano | Grant A | 2.3K | $0 |
| Feb 9, 2026 | David S. Rosenbloom | Other F | 5.2K | $113.5K |
| Feb 9, 2026 | David S. Rosenbloom | Grant A | 17.1K | $0 |
| Feb 9, 2026 | Reazur Rasul | Other F | 5.8K | $125.4K |
| Feb 9, 2026 | Reazur Rasul | Grant A | 19.0K | $0 |
| Feb 9, 2026 | Joel T. Grade KEY | Other F | 9.1K | $198.7K |
| Feb 9, 2026 | Joel T. Grade KEY | Grant A | 30.5K | $0 |
About BAX insider trading
This page tracks insider transactions for BAXTER INTERNATIONAL INC (BAX) reported to the U.S. Securities and Exchange Commission on Form 4. Corporate insiders — directors, executive officers and beneficial owners of more than 10% of the stock — must disclose their trades within two business days. Open-market purchases (code P) and sales (code S) made at the insider's discretion are the most-watched opportunistic signals, while awards (A), option exercises (M) and tax-withholding (F) reflect compensation rather than conviction. Trades marked 10b5-1 were made under a pre-arranged plan and are considered routine. A cluster buy — several insiders buying within a short window — is historically a stronger bullish indicator than any single trade.